Source:http://linkedlifedata.com/resource/umls/id/C1527027
PDQ: A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), thereby affecting the regulation of gene expression and inducing cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several HSP90-dependent oncoproteins. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42600&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42600&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1544" NCI Thesaurus),NCI: A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and